- Home
- PSBD vs BCYC Comparison
PSBD vs BCYC Comparison
Compare PSBD & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- BCYC
- Stock Information
- Founded
- PSBD 2009
- BCYC 2009
- Country
- PSBD United States
- BCYC United Kingdom
- Employees
- PSBD N/A
- BCYC N/A
- Industry
- PSBD
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- PSBD
- BCYC Health Care
- Exchange
- PSBD Nasdaq
- BCYC Nasdaq
- Market Cap
- PSBD 440.2M
- BCYC 511.4M
- IPO Year
- PSBD 2024
- BCYC 2019
- Fundamental
- Price
- PSBD $12.81
- BCYC $7.39
- Analyst Decision
- PSBD Hold
- BCYC Buy
- Analyst Count
- PSBD 3
- BCYC 8
- Target Price
- PSBD $16.17
- BCYC $29.14
- AVG Volume (30 Days)
- PSBD 55.3K
- BCYC 438.9K
- Earning Date
- PSBD 05-07-2025
- BCYC 05-01-2025
- Dividend Yield
- PSBD 14.17%
- BCYC N/A
- EPS Growth
- PSBD N/A
- BCYC N/A
- EPS
- PSBD N/A
- BCYC N/A
- Revenue
- PSBD N/A
- BCYC $35,275,000.00
- Revenue This Year
- PSBD N/A
- BCYC N/A
- Revenue Next Year
- PSBD N/A
- BCYC $0.27
- P/E Ratio
- PSBD N/A
- BCYC N/A
- Revenue Growth
- PSBD N/A
- BCYC 30.76
- 52 Week Low
- PSBD $11.89
- BCYC $6.10
- 52 Week High
- PSBD $17.02
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- PSBD 37.79
- BCYC 40.27
- Support Level
- PSBD $12.29
- BCYC $6.10
- Resistance Level
- PSBD $13.58
- BCYC $8.00
- Average True Range (ATR)
- PSBD 0.88
- BCYC 0.61
- MACD
- PSBD 0.02
- BCYC 0.14
- Stochastic Oscillator
- PSBD 37.25
- BCYC 46.07
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.